Entracid-LS Capsule is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed for the effective management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Esomeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing symptomatic relief and promoting healing in acid-related conditions. The combined action of Levosulpiride and Esomeprazole makes Entracid-LS particularly effective in treating gastroesophageal reflux disease (GERD), functional dyspepsia, gastritis, and peptic ulcer disease. This capsule formulation is intended for oral administration, with dosing tailored according to clinical response and physician guidance. Entracid-LS offers a dual mechanism approach, addressing both motility dysfunction and acid hypersecretion, thereby improving patient outcomes in complex gastrointestinal pathologies. Caution is advised in patients with known hypersensitivity to either component, and use during pregnancy or lactation should be under strict medical supervision. Regular monitoring is recommended to assess therapeutic efficacy and detect potential adverse effects.